Novel Hepatitis C Treatments Gets a Leg Up From the Increasing Number of Diagnosed Cases, Finds Frost & Sullivan
SINGAPORE, July 26 The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects. Compounding the issue is that lower efficacy often results in patient non-compliance of extended treatment, which is often needed for 50 percent of patients with HCV genotype 1 - the most prevalent genotype in Singapore.
New analysis from Frost & Sullivan (http://www.pharma.frost.com), Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore, finds that the market earned revenues of $2.3 billion in 2007 and is expected to increase to approximately $4.5 billion by 2017 due to anticipated drug launches post 2010.
"According to physicians, those afflicted with Hepatitis C genotype 1 have a sustained viral response of 50 percent to current therapies, resulting in prolonged treatment and patient noncompliance," says Frost & Sullivan Industry Analyst, Jennifer Lau. "With 75 percent of those diagnosed with Hepatitis C in Singapore having genotype 1 strain, the current drug offerings are unable to capture a sizeable portion of the market."
The current treatment regimen of Pegylated Interferon and Ribavirin for Hepatitis C has strong side effects such as developing autoimmune syndromes, neuropsychiatric disorders. The treatment also has a much lower efficacy for the genotype 1 strain, leading to patient noncompliance. These issues translate to missed treatment opportunities.
Companies that explore new treatments, which improve efficacy, decrease side effects, and increase compliance, are very likely to succeed in the market. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and a new drug class known as protease inhibitors are in the pipeline and represent the future of HCV treatment.
Creating incentives for patients to continue the course of the current HCV treatment will increase the rate of patient compliance with new and improved treatments.
"In order to increase their HCV market share with newer drugs, companies must ensure that patients are aware of their disease status and are willing to try new treatments," notes Lau. "Creating marketing campaigns highlighting increase drug efficacy as well as partnerships with governments to lower costs and increase distribution will enhance their market presence."
If you are interested in more information on this study, please send an e-mail to Nicklaus Au, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: Opportunities Assessment of Hepatitis C Market in Thailand, Opportunities Assessment of Hepatitis C in Philippines, Opportunities Assessment of Hepatitis C in Indonesia, Opportunities Assessment of Hepatitis C in Hong Kong, Opportunities Assessment of Hepatitis C in Australia, Opportunities Assessment of Hepatitis C in China, Opportunities Assessment of Hepatitis C in Taiwan, Opportunities Assessment of Hepatitis C in India, Opportunities Assessment of Hepatitis C in South Korea, and Opportunities Assessment of Hepatitis C in Malaysia. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
Contact: Nicklaus Au Corporate Communications - Asia Pacific P: +603 6204 5836 F: +603 6201 7402 E: email@example.com Donna Jeremiah Corporate Communications - Asia Pacific P: +603 6204 5832 F: +603 6201 7402 E: firstname.lastname@example.org
SOURCE Frost & Sullivan
You May Also Like